Results

Total Results: 1,939 records

Showing results for "event".

1921. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
      March 01, 2012 - renal insufficiency or development of dialysis dependence. 3 Impact of changing trends in outcome event … This may reflect low event rates among otherwise healthy patients and relatively few studies with extended … Although several studies collected data on angioedema, the event rates were very low or zero for all … In the four studies that did report episodes of angioedema, this adverse event was observed only in … Impact of changing trends in outcome event rates over time on the comparative effectiveness of ACEI,

1922. The Effectiveness of Disease-Modifying Antirheumatic Drugs (DMARDS) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research-protocol
      March 09, 2010 - We will review the quarterly data files from the United States Food and Drug Administration Adverse Event … TEP Technical Expert Panel TNF Tumor Necrosis Factor Summary of Protocol Amendments In the event

1923. renal-update-2015-150115 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-update_research-protocol.pdf
      January 15, 2015 - lipid-lowering drugs) • Surgical repair Outcomes • Mortality, all cause • Kidney function o Event … therapy) o Categorical (eg, better/worse) o Continuous (ie, GFR, CrCl, SCr) • Blood pressure o Event

1924. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research
      September 26, 2011 - Current Page Topic Timeline Jan. 14, 2008 Topic Suggestion Mar. 9, 2010 Research Protocol Sep. 26, 2011 Systematic Review Jan. 4, 2012 Disposition of Comments Report Jul. 3, 2013 Surveillance Report Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Systematic Review…

1925. Atrial-Fibrillation-Ablation Surveillance (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_surveillance.pdf
      May 16, 2013 - There were 84 studies that reported at least one adverse event associated with RFA. … percent to 5 percent (median 1 percent) of patients in the 70 studies that reported this adverse event … Atrioesophageal fistula was reported in 26 studies: 5 studies reported 1 case each, with event rates … embolism n=1 (0.17%) 15.2% vs. 2.4%, p<0.001 [KMA] (CHADS2 score > 2 as a predictor of adverse event … pulmonary vein ablation; CPVA-CM= circumferential pulmonary vein ablation circular mapping; AE=adverse event

1926. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update of the 2007 Report | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/type-2-diabetes-medications-update/research-protocol
      April 05, 2010 - Current Page Topic Timeline Feb. 1, 2010 Topic Initiated Apr. 5, 2010 Research Protocol Mar. 15, 2011 Systematic Review May. 27, 2014 Surveillance Report Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update of the 2007 Report Research Protocol Archived April …

1927. Procalcitonin for Diagnosis and Management of Sepsis | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/procalcitonin/research-protocol
      April 26, 2011 - Current Page Topic Timeline Jun. 17, 2009 Topic Suggestion Apr. 26, 2011 Research Protocol Oct. 5, 2012 Systematic Review Dec. 10, 2012 Disposition of Comments Report Procalcitonin for Diagnosis and Management of Sepsis Research Protocol Archived April 26, 2011 Download Main Document PDF 313.1 KB On …

1928. Untitled (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/thromboembolism-update_research-protocol.pdf
      February 17, 2016 - Untitled   Source: www.effectivehealthcare.ahrq.gov Published online: February 17, 2016 Evidence-based Practice Center Systematic Review Protocol Project Title: Systematic Review Update of Venous Thromboembolism Prophylaxis in Orthopedic Surgery I. Background and Objectives for the Systematic Review Ma…

1929. Layout 1 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-insulin_executive.pdf
      September 01, 2008 - Layout 1 Background and Key Questions Although oral antidiabetic agents are used as first-line agents in patients with type 2 diabetes, insulin is required in a significant number of patients at some stage during the management of diabetes to maintain optimal glycemic control. Insulin use has been suggested as a fir…

1930. Stroke Prevention in Atrial Fibrillation Patients: A Systematic Review Update | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/stroke-afib-update/research-protocol
      July 07, 2017 - , dementia) When in therapeutic range When non-adherent to medication Previous thromboembolic event … patient characteristics; clinical settings; diagnostic tools; and intermediate, final, and adverse event … Example factors include narrow eligibility criteria and exclusion of those with comorbidities, event … Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event

1931. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-anemia-update_research-protocol.pdf
      June 16, 2010 - Time to event data, e.g., overall survival, will be calculated as hazard ratios (HR) based on individual … OR “adverse effect*” OR “adverse drug reaction*” OR “side effect*” OR “toxic effect*” OR “adverse event

1932. ASSESSING THE QUALITY OF INCLUDED STUDIES (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/assessing-the-risk-of-bias_draft-report.pdf
      June 02, 2011 - Since many harms are not anticipated (the severity, the type of event -especially rare events, the … timing of the event, etc.), many studies do not specify exact protocols to actively capture events. … There is also the issue of establishing an association between the event and the intervention. … Is there a plausible biological mechanism linking the intervention to the adverse event? … Did the author(s) specify the NUMBER for each TYPE of harmful event for each study group? 15.

1933. Procalcitonin-Guided Antibiotic Therapy | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/procalcitonin/research
      October 05, 2012 - Current Page Topic Timeline Jun. 17, 2009 Topic Suggestion Apr. 26, 2011 Research Protocol Oct. 5, 2012 Systematic Review Dec. 10, 2012 Disposition of Comments Report Procalcitonin-Guided Antibiotic Therapy Systematic Review Archived October 5, 2012 Web Version [NLM Site] Download Main Document PDF 2.1 MB …

1934. Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/nephropathy-contrast-induced_clinician.pdf
      August 01, 2016 - Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN Focus of This Summary This is a summary of two systematic reviews. One review evaluated the evidence regarding the comparative effects of different contrast media in patients requiring diagnostic imaging studies…

1935. Layout 1 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/head-neck-cancer_executive.pdf
      May 01, 2010 - Layout 1 Background Head and neck cancers, specifically those arising in the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, paranasal sinuses/nasal cavity, salivary glands, and occult primaries, account for approximately 3 to 5 percent of cancers in the United States. According to the National Comprehens…

1936. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis – An Update to the 2006 Report | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/osteoarthritis-pain/research-protocol
      August 05, 2010 - NSAIDs—nonaspirin, nonselective NSAIDs, or simply nonselective NSAIDs Summary of Protocol Amendments In the event

1937. Comparative Effectiveness of Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m² | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/weight-loss-surgery/research-protocol
      December 14, 2010 - In the event that data are lacking, an assessment should be made to determine which key variables influence … Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

1938. Inguinal-Hernia Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/inguinal-hernia_executive.pdf
      August 01, 2012 - 1 Comparative Effectiveness Review Number 70 Surgical Options for Inguinal Hernia: Comparative Effectiveness Review Executive Summary Background An inguinal hernia is a protrusion of abdominal contents into the inguinal canal through an abdominal wall defect. The lifetime rate of inguinal hernia is 25 perc…

1939. Methods Guide for Medical Test Reviews Chapter 9 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-performance_methods.pdf
      July 01, 2012 - information on the presence or absense of the condition of interest, or predict the occurrence of a future event